|1.||Del Signore, Susanna: 5 articles (12/2006 - 09/2002)|
|2.||Fedorova, N V: 3 articles (01/2015 - 01/2003)|
|3.||Rascol, Olivier: 3 articles (02/2010 - 04/2003)|
|4.||Schrag, Anette: 2 articles (09/2015 - 01/2008)|
|5.||Jost, Wolfgang: 2 articles (07/2014 - 04/2006)|
|6.||Tschopp, Lorena: 2 articles (01/2012 - 01/2010)|
|7.||Micheli, Federico: 2 articles (01/2012 - 01/2010)|
|8.||Micallef, Joëlle: 2 articles (11/2011 - 07/2005)|
|9.||Millan, Mark J: 2 articles (11/2010 - 11/2006)|
|10.||Blin, Olivier: 2 articles (02/2010 - 07/2005)|
|1.||Parkinson Disease (Parkinson's Disease)
03/01/1999 - "This randomized, double-blind trial was designed to evaluate the efficacy of a transdermal system of piribedil on the motor symptoms of Parkinson's disease during 3 weeks of treatment administered to three different groups: placebo, one piribedil patch (1 PP), and two (2 PP) piribedil patches. "
02/01/1989 - "We conducted a 20-week nonblind study to evaluate the efficacy of piribedil in 30 patients with idiopathic Parkinson's disease (PD). "
05/01/2001 - "After an in vitro-in vivo evaluation of piribedil solid lipid particles developed for Parkinson's disease therapy, it has been determined that release rate could be controlled and piribedil bioavailability could be improved."
11/01/2013 - "A study based on the French national pharmacovigilance database identified and analysed 7 reports of sleep attacks attributed to piribedil in patients without Parkinson's disease. "
12/01/2006 - "Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study."
09/01/2002 - "In contrast, administration of piribedil produced a significantly lower degree and intensity of dyskinesia. "
05/01/2006 - "However, on switching from piribedil to levodopa, the rapid increase in dyskinesia despite the improvement in motor function being maintained suggests that piribedil also primes for but does not markedly express dyskinesia. "
01/01/2012 - "Piribedil doses were decreased to 200 mg/d and levodopa increased up to 750 mg/d, with a clear improvement in compulsive behavior without worsening of the dyskinesia.Our"
05/01/2006 - "On switching from levodopa to piribedil, the intensity of dyskinesia decreased without altering the improvement in motor deficits. "
05/01/2006 - "The study confirms the low dyskinesia expression resulting from piribedil treatment compared with an equieffective dose of levodopa. "
08/01/2009 - "There was no significant improvement of Tinnitus Handicap Inventory and visual analog scale score after piribedil treatment as compared with placebo. "
08/01/2009 - "Piribedil treatment responders differed from nonresponders by specific findings in the ECoG and in the distortion product acoustic otoacoustic emissions, suggesting a beneficial effect of piribedil in an electrophysiologically characterized tinnitus subgroup."
08/01/2009 - "Piribedil is not superior to placebo in the treatment of tinnitus. "
08/01/2009 - "To assess the efficacy and safety of the dopaminergic drug piribedil for the treatment of tinnitus and to evaluate whether ECoG and acoustic otoemissions might be useful for predicting treatment response. "
08/01/2009 - "Tinnitus treatment with piribedil guided by electrocochleography and acoustic otoemissions."
01/01/1975 - "The usefulness of piribedil against some forms of human tremor and its low-intensity antiakinetic action probably result from this pattern of pharmacologic activity."
01/01/1992 - "Piribedil is used in the symptomatic treatment of Parkinson's disease and is particularly effective against tremor. "
09/01/1984 - "Piribedil decreased tremor but facilitated EMG activity in tardive dyskinesia. "
04/16/2004 - "Piribedil is a D2 D3 dopamine agonist, which has been shown to be well tolerated and to improve Parkinsonian symptoms, particularly tremor. "
05/01/2001 - "Suspensions of pure piribedil and a formulation, selected according to the results obtained from in vitro dissolution and particle size experiments, were compared using tremor tests in mice. "
01/01/1981 - "Subsequently, dose- and time-response analyses established that AP decreased PTZ seizure threshold 15 min after administraton, but increased the threshold at 60 min. Piribedil elevated the seizure threshold, but like AP, did not exhibit a clear dose-response relationship. "
06/01/1976 - "A series of ergot alkaloids, together with the DA agonists apomorphine and piribedil, were tested for protective effects against audiogenic seizures in an inbred strain of mice (DBA/2) and for induction of circling behaviour in mice with unilateral destruction of one nigrostriatal DA pathway. "
01/01/1981 - "Atropine also decreased the AP-induced increase in threshold at 60 min. The pattern of inhibition of seizure threshold changes induced by the neurotransmitter blockers suggested that piribedil blocked seizures by means of indirect actions on several neurotransmitters."
01/01/1981 - "Effects of apomorphine and piribedil on pentylenetetrazol-induced seizures in mice."
03/01/1975 - "Effects of apomorphine, ergocornine and piribedil on audiogenic seizures in DBA/2 mice."
|1.||Dopamine Agonists (Dopamine Agonist)
|2.||Levodopa (L Dopa)
|4.||Dopamine Receptors (Dopamine Receptor)
|5.||Serotonin (5 Hydroxytryptamine)
|8.||Morphine (MS Contin)
|2.||Deep Brain Stimulation
|3.||Continuous Positive Airway Pressure